

10/571511

APR 9 Rec'd PCT/PTO 10 MAR 2009

PATENT

Customer No. 22,852

Attorney Docket No. 10084-0004.00000

Client Ref. : FP-039PCT-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
Toshio DOI et al.	)	Group Art Unit:
	)	
Application No.: Not yet assigned	)	Examiner:
	)	
Filed: Concurrently herewith	)	
	)	
For: METHOD AND KIT FOR DETECTING PROLIFERATIVE	)	Confirmation No.:
DISEASES CAUSING SCLEROSIS, PREVENTIVE	)	
AND/OR REMEDY FOR PROLIFERATIVE DISEASES	)	
CAUSING SCLEROSIS AND METHOD AND KIT FOR	)	
IDENTIFYING SUBSTANCE EFFICACIOUS IN	)	
PREVENTING AND/OR TREATING PROLIFERATIVE	)	
DISEASES CAUSING SCLEROSIS	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicant brings to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage in an international application.

Copies of the listed foreign and non-patent literature documents are attached. Copies of the U.S. patent publications are not enclosed.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: 3/10/06

By: 

Chris T. Mizumoto  
Reg. No. 42,899

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Application Number		Not yet assigned	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Filing Date		Concurrently herewith	
				First Named Inventor		Toshio DOI et al.	
				Art Unit			
				Examiner Name			
				Attorney Docket Number		10084-0004 00000	
Sheet	1	of	1				

## U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No.	Document Number Number-Kind Code <sup>2</sup> (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-			
	AB	US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
/ECK/	BA	WO 03/042211 A1	05-22-2003	SMITHKLINE BEECHAM CORP	claims: page 1, lines 8 to 24	
	BB					

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
/ECK/	CA	International Search Report for application No. PCT/JP2004/013124, mailed November 30, 2004	
	CB	Horiguchi, A. et al., "Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome", J. Urol., (2002 August), Vol. 168, No.2, pages 762 to 765	
	CC	Wang, X. et al., "Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells", Diabetes, (2002 December), Vol 51, No.12, pages 3505 to 3509	
	CD	Huang, J.S. et al., "Role of the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells", Biochem.J., (1999 August), Vol.15, No.342 (Pt.1), pages 231 to 238	
	CE	Wang, S.N. et al., "Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy", J.Am.Soc.Nephrol., (2001 November), Vol.12, No.11, pages 2392 to 2399	
	CF	Yang, C.W. et al., "Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease", Proc. Natl. Acad.Sci.USA, (1994), Vol.91, No.20, pages 9436 to 9440	
	CG	Paul Oh, S. et al., "Activin receptor-like kinase 1 modulates transforming growth factor-β 1 signaling in the regulation of angiogenesis", Proc. Natl. Acad. Sci. USA, (2000), Vol.97, No.6, pages 2626 to 2631	
	CH	Gupta, I.R. et al., "BMP-2/ALK3 and HGF signal in parallel to regulate renal collecting duct morphogenesis", J.Cell Sci., (2000 January), Vol.113, Pt.2, pages 269 to 278	
	CI	Abe, H. et al., "Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product (AGE) stimulation", J. Biol. Chem., (2004 April), Vol.279, No.14, pages 14201 to 14206	

Examiner Signature	/Elizabeth C. Kemmerer/	Date Considered	11/05/2008
--------------------	-------------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.